AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.

@article{Raghavan2012AZD5438AI,
  title={AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.},
  author={Pavithra Raghavan and Vasu Tumati and Lan Yu and Norman Y. M. Chan and Nozomi Tomimatsu and Sandeep Burma and Robert G. Bristow and Debabrata Saha},
  journal={International journal of radiation oncology, biology, physics},
  year={2012},
  volume={84 4},
  pages={e507-14}
}
PURPOSE Radiation therapy (RT) is one of the primary modalities for treatment of non-small cell lung cancer (NSCLC). However, due to the intrinsic radiation resistance of these tumors, many patients experience RT failure, which leads to considerable tumor progression including regional lymph node and distant metastasis. This preclinical study evaluated the efficacy of a new-generation cyclin-dependent kinase (Cdk) inhibitor, AZD5438, as a radiosensitizer in several NSCLC models that are… CONTINUE READING
10 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…